Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases

This study has been terminated.
(underfunding)
Sponsor:
Information provided by:
Central European Cooperative Oncology Group
ClinicalTrials.gov Identifier:
NCT00294437
First received: February 20, 2006
Last updated: April 30, 2012
Last verified: April 2012
  Purpose

To determine if therapy with Zometa® (zoledronic acid) 4mg will be effective in preventing the occurrence of bone metastases in prostate cancer patients at high risk of developing them. In addition, pain and analgesic scores and overall safety are to be evaluated throughout the study.


Condition Intervention Phase
Prostate Cancer
Drug: Zometa
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomised Open-label Multicenter Prosp. Clinical Study to Show the Efficacy of IV ZOMETA® 4mg for Prevention of Bone Metastases in Hormone-naïve High Risk Patients With Locally Advanced Prostate Cancer

Resource links provided by NLM:


Further study details as provided by Central European Cooperative Oncology Group:

Primary Outcome Measures:
  • Time to occurrence of first bone metastasis, as assessed by bone scan and confirmed by additional radiological examination

Secondary Outcome Measures:
  • To assess the effects of i.v. Zometa® (zoledronic acid) 4 mg, with respect to the following efficacy parameters as well as safety and tolerability:
  • Effects on pain and analgesic drug consumption, assessed by the composite pain score from BPI (Brief Pain Inventory) for pain and by analgesic score
  • Time to first event of bone pain
  • Time to first occurrence of Skeletal Related Events (SREs), defined as pathologic bone fractures, spinal cord compression, surgery to bone, radiation therapy to bone (including the use of radioisotopes)
  • Proportion of patients in each arm having SRE
  • Serum PSA
  • Overall safety

Enrollment: 376
Study Start Date: December 2003
Study Completion Date: November 2007
Primary Completion Date: December 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: zoledronic acid
Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months
Drug: Zometa
Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months
No Intervention: no intervention
no reference therapy

Detailed Description:

This is a prospective, randomized, stratified open-label (Zometa + hormonal ablation versus hormonal ablation alone) multicenter clinical study evaluating the efficacy of Zometa 4mg given every 3 month as an adjunct to hormonal or surgical castration for prevention of bone metastases in locally advanced, high risk prostate cancer patients, who are hormone-naiv at time of randomization. the primary efficacy variable is the time to occurrence of first bone metastases.

Zometa® (zoledronic acid) provided as 4mg lyophilised powder Supplementation 500mg Calcium +400-500IU Vitamin D p.o. qd

Arm A:

Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months

Arm B:

no reference therapy

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent
  • Age > 18 years
  • Histologically confirmed diagnosis of carcinoma of the prostate
  • ECOG performance status of 0, 1, or 2
  • No radiological evident bone metastasis (negative bone scan or verification of suspected foci as benign lesions by additional radiological examination)
  • T3-4 AND highest pre-study PSA >20 ng/ml AND Gleason score = 8 (or Gleason grade = 4)
  • Patients with prior prostatectomy or prior local radiotherapy are eligible for this study
  • Patients are destined to receive medical (LHRH analogue) or surgical (orchiectomy) castration and Zometa® treatment will start not later than 6 weeks after surgery
  • Patients should be fully recovered from prior interventions where applicable

Exclusion Criteria:

  • Patients with a serum creatinine determination >265 µmol/L (3.0 mg/dL)
  • Patients that received prior medical (LHRH analogue) castration
  • Current (or previous) evidence of metastatic disease to the bone
  • History of any other neoplasm within the past five years except for nonmelanomatous skin cancer.
  • Previous hormonal therapy with LHRH agonists or other forms of hormonal ablation
  • WBC<3.0x109, ANC < 1500/mm3, Hgb<8.0 g/dL, platelets < 75 x 109/L
  • Liver function tests >2.5 ULN
  • Prior treatment with Zometa® (zoledronic acid) or other bisphosphonates
  • Treatment with calcitonin, mithramycin, or gallium nitrate within 2 weeks prior to the date of randomization (Visit 2)
  • Use of other investigational drugs (drugs not marketed for any indication) within 30 days prior to the date of randomization (Visit 2)
  • Patients with evidence in the six months prior to randomization of severe cardiovascular disease (defined as uncontrolled congestive heart failure), hypertension refractory to treatment, or symptomatic coronary artery disease uncontrolled by treatment
  • History of noncompliance to medical regimens and patients who are considered potentially unreliable or incapable of giving informed consent as judged by the investigator.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00294437

  Hide Study Locations
Locations
Austria
LKH Leoben, Abt. für Innere Medizin
Leoben, Steiermark, Austria, 8700
Thermenkh Baden, Urologie
Baden bei Wien, Austria
LKH Graz Univ. Klinik f Urologie
Graz, Austria
LKH Innsbruck, Dept f. Urologie
Innsbruck, Austria
KH d Elisabethinen Linz, Dep of Urology
Linz, Austria
KH der Barmherzigen Schwestern, Dept Urologie
Linz, Austria
LKH Salzburg, Clinic f Radiotherapy a Radiooncology
Salzburg, Austria
Bosnia and Herzegovina
Institute for Oncology
Sarajevo, Bosnia and Herzegovina
Bulgaria
Plovdiv Cancer Center
Plovdiv, Bulgaria, 4000
SBALO National Oncology Center
Sofia, Bulgaria, 1527
SBALO National Oncology Center
Sofia, Bulgaria
Sofia Cancer Center compl. Mladost ,
Sofia, Bulgaria
MODOSZ Oncology Dispensary
Stara Zagora, Bulgaria
Modozs-Veliko
Tarnovo, Bulgaria
Oncological Hospital
Varna, Bulgaria
Croatia
Univ. Hospital, Dep of Pathophysiology
Split, Croatia
GH, Dep Oncology and Reumatology
Varazdin, Croatia
Clinical Hospital
Zagreb, Croatia
Czech Republic
FH, Urological Clinic
Brno, Czech Republic
Hospital Kromeriz, Dep of Urology
Kromeriz, Czech Republic
FN Motol, Dep of Urology
Prague, Czech Republic
Centre of Oncology
Usti Nad Labem, Czech Republic
Estonia
Mustamae Korpus
Tallinn, Estonia
Clinic of surgery
Tartu, Estonia
Hungary
Dept. Of Urology , Jahn Ferenc Delpesti Hospital
Budapest, Hungary
karolyi sandor Hospital, Dept of Urology
Budapest, Hungary
Semmelweiss Univ of Medicine, Clinic of Urology
Budapest, Hungary
Univ. of Pecs,Urologic Clinic
Pecs, Hungary
Dept. Of Urology and Surgery
Szombathely, Hungary
Lithuania
Lithuanian Oncology Center
Vilnius, Lithuania
Montenegro
Clinical Center of Montenegro
Podgorica, Montenegro
Poland
Centrum Onkologii Instytut
Krakow, Poland
Medical Academy
Szczecin, Poland
Medical Academy
Warsaw, Poland
Central Rail Hospital,
Warsaw, Poland
Romania
P.D.R. Clinic
Brasov, Romania
Fundeni Hospital, Dep of Urology
Bucharest, Romania
Saint John Emergency Clinical Hospital
Bucharest, Romania
Institutul Oncologic Cluj
Cluj-Napoca, Romania, 400015
Emergency Clinical County Hospital , Clin Oncol. Dep
Craiova, Romania
University Hospital
Iasi, Romania
Russian Federation
Hertzen Research Oncological Institute
Moscow, Russian Federation
Medical Radiological Research Center
Obninsk, Russian Federation
Serbia
Clinical Center of Serbia
Belgrade, Serbia
Oncology Institute
Belgrade, Serbia
Oncology Institute Belgrade
Belgrade, Serbia
Clinical Center
Nis, Serbia
Institute for Oncology
Sremska Kamenica, Serbia
Slovakia
FNsP - akad L. Derea Urology
Bratislava, Slovakia
FNsP Dep of Urology
Kosice, Slovakia
FN sP Dep of Urology
Martin, Slovakia
Slovenia
University Clinical Center
Ljubljana, Slovenia
Gh, Dep of Urology
Maribor, Slovenia
South Africa
Turret House
Claremont, South Africa
Johannesburg Hospital Dep of Urology
Johannesburg, South Africa
St. Annes Hospital
Pietermaritzburg, South Africa
Urological Hospital
Pretoria, South Africa
Sponsors and Collaborators
Central European Cooperative Oncology Group
Investigators
Principal Investigator: Bobak Djavan, Prof Univ. Klinik für Urologie
  More Information

Additional Information:
No publications provided

Responsible Party: CECOG
ClinicalTrials.gov Identifier: NCT00294437     History of Changes
Other Study ID Numbers: CECOG/prostate 1.2.001
Study First Received: February 20, 2006
Last Updated: April 30, 2012
Health Authority: Austria: Federal Ministry for Health and Women

Keywords provided by Central European Cooperative Oncology Group:
Prostate Cancer
Zometa

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Zoledronic acid
Bone Density Conservation Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on November 19, 2014